International Journal of Nephrology and Renovascular Disease, 2023 Rey Isidto,1 Romina Danguilan,2 Oscar Naidas,3 Russell Vilanueva,2 Mel-Hatra Arakama,2 Layla Marie Paraiso2 1HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2Department of Adult Nephrology, National ...
Isidto R +5 more
doaj
SGLT2 Inhibitors and the Diabetic Kidney [PDF]
, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression ...
Busetto, Luca +4 more
core +1 more source
Eligibility of outpatients with chronic heart failure for sodium–glucose co‐transporter‐2 inhibitors
ESC Heart Failure, 2021 Aims Sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) have been shown to have a relevant role in the prevention of hospitalizations for heart failure and improvement in the life expectancy of patients with diabetes and outpatients with chronic heart ...
Gianmarco Angelini +11 more
doaj +1 more source
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Biomolecules, 2022 Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is)
Francesca Romana Prandi +8 more
doaj +1 more source
Metabolic and cardiac adaptation to chronic pharmacologic blockade of facilitative glucose transport in murine dilated cardiomyopathy and myocardial ischemia [PDF]
, 2018 GLUT transgenic and knockout mice have provided valuable insight into the role of facilitative glucose transporters (GLUTs) in cardiovascular and metabolic disease, but compensatory physiological changes can hinder interpretation of these models.
Heitmeier, Monique R. +6 more
core +2 more sources
Fournier's gangrene and sodium-glucose co-transporter 2(SGLT2) inhibitors: Our experience
Indian Journal of Endocrinology and Metabolism, 2019 Ashwitha S Dass +2 more
doaj +3 more sources
New Diabetes Therapies and Diabetic Kidney Disease Progression:the Role of SGLT-2 Inhibitors [PDF]
, 2018 Purpose of Review Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney disease.
Dekkers, Claire C. J. +2 more
core +2 more sources
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes [PDF]
, 2020 Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage.
Alves-Martinez, Pilar +8 more
core +1 more source
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
Drugs in Context, 2014 Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
doaj +1 more source
Российский кардиологический журнал, 2021 The development of chronic kidney disease (CKD) is a risk factor not only for cardiovascular diseases, but also for heart failure (HF). This article is a literary review on the use of Sodium-glucose co-transporter-2 (NGLT2) inhibitors in patients with ...
M. M. Batyushin
doaj +1 more source